This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Thoratec's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Turning to our results for the first half of 2012, revenues were $245.4 million representing an increase of 16% versus the first half of 2011, or 15% excluding the impact of foreign exchange and acquisitions. During the first half of the year, our performance was driven by HeartMate revenue growth of 18%, which more than offset the 36% decline in our PVAD franchise, which I mentioned previously. Growth in this period was relatively balanced across geographies with domestic revenues increasing 15% and international revenues increasing 18% excluding foreign exchange and acquisitions.

Earnings on non-GAAP basis were $0.96 per share during the first six months of 2012, an increase of 25%. Unit growth of HeartMate II has been quite encouraging and has driven our overall financial performance, both in the second quarter and the first six months of 2012. For Q2, HeartMate II units grew 13% year-over-year against a very strong prior year quarter. In the U.S. where the quarterly comparison was the most difficult, HeartMate II unit growth was 8%, while internationally we achieved 32% growth for the second quarter in a row.

This performance brought first half unit growth for HeartMate II to 19% domestically and 22% on a worldwide basis. It is the destination therapy indication that has driven HeartMate II growth in recent periods, and the past two quarters have been no exception with DT implants rising to over 45% of our domestic HeartMate II sales in the first half of the year. Looking forward, we continue to expect the DT indication to account for the vast majority of growth in the VAD market.

Read the rest of this transcript for free on

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.16 -1.80%
FB $116.12 -0.52%
GOOG $689.61 -0.20%
TSLA $241.76 -2.40%
YHOO $36.32 -0.74%


Chart of I:DJI
DOW 17,694.96 -135.80 -0.76%
S&P 500 2,054.17 -21.64 -1.04%
NASDAQ 4,746.3360 -58.9550 -1.23%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs